MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:39Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Mucosal protectants]]
			[[Category:Anti-ulcer agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #240

2026-05-23T04:04:21Z

parser-claude batch MedTemplate pre-fill, Top 300 #240

New page

{{MedTemplate
| generic = Sucralfate
| brand = Carafate
| structure =
| classes = [[:Category:Mucosal_protectants|Mucosal protectant]], [[:Category:Anti-ulcer_agents|Anti-ulcer agent]]
| uses = <vote slug="duodenal-ulcer-use">Duodenal ulcer (active treatment and maintenance)</vote>, <vote slug="stress-ulcer-prophylaxis-use">Stress ulcer prophylaxis</vote>, <vote slug="oral-mucositis-use">Radiation-induced oral mucositis (off-label slurry)</vote>, <vote slug="bile-reflux-gastritis-use">Bile reflux gastritis</vote>
| starting_dose = 1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance
| preparations = 1 g tablets; 1 g/10 mL suspension
| fda_max = 4 g/d typical
| pill_id =
| routes = Oral
| onset = Mucosal protection within hours; ulcer healing over 2-4 weeks
| duration = 6 hours per dose
| halflife = Not meaningfully described — sucralfate is essentially non-absorbed<ref name="carafate-label">FDA Prescribing Information, Carafate (sucralfate), Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019183s050lbl.pdf</ref>
| bioavailability = <5% systemic absorption (this is the safety basis)<ref name="carafate-label" />
| pregnancy = Generally considered safe due to minimal systemic absorption.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="sucralfate-mech-claim">Sucralfate is a complex of sucrose octasulfate and polyaluminum hydroxide; in the acidic gastric environment it polymerizes into a viscous, sticky gel that selectively binds ulcer crater protein exudates, forming a physical protective barrier over ulcer beds without changing acid secretion.</vote> Also stimulates local prostaglandin and mucus production. Substantial impact on absorption of co-administered drugs (binds tetracyclines, fluoroquinolones, digoxin, levothyroxine, warfarin) — separate dosing windows by ≥2 hours. Aluminum accumulation in advanced CKD is the systemic-toxicity concern<ref name="carafate-label" />.
}}

== References ==
<references />

Sucralfate - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #240